Myriad Genetics Inc MYGN
We take great care to ensure that the data presented and summarized in this overview for MYRIAD GENETICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MYGN
View all-
Black Rock Inc. New York, NY15.2MShares$69.5 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.7MShares$49 Million0.0% of portfolio
-
State Street Corp Boston, MA5.27MShares$24.2 Million0.0% of portfolio
-
Disciplined Growth Investors Inc Minneapolis, MN4.73MShares$21.7 Million0.98% of portfolio
-
Wellington Management Group LLP Boston, MA4.59MShares$21.1 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.07MShares$18.7 Million0.02% of portfolio
-
Earnest Partners LLC Atlanta, GA3.98MShares$18.3 Million0.18% of portfolio
-
Glenview Capital Management, LLC New York, NY3.9MShares$17.9 Million0.85% of portfolio
-
Bank Of America Corp Charlotte, NC2.63MShares$12.1 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.52MShares$11.6 Million0.02% of portfolio
Latest Institutional Activity in MYGN
Top Purchases
Top Sells
About MYGN
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Insider Transactions at MYGN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 05
2025
|
Colleen F Reitan Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,796
+35.04%
|
-
|
Jun 05
2025
|
Lee Nisley Newcomer Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,796
+27.37%
|
-
|
Jun 05
2025
|
S. Louise Phanstiel Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,796
+21.91%
|
-
|
Jun 05
2025
|
Mark Steven Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
24,148
+33.96%
|
-
|
Jun 05
2025
|
Paul Bisaro Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,796
+35.64%
|
-
|
Jun 05
2025
|
Heinrich Dreismann Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,796
+22.51%
|
-
|
Jun 05
2025
|
Daniel Skovronsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,796
+26.83%
|
-
|
Jun 05
2025
|
Rashmi Kumar Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,796
+28.14%
|
-
|
May 31
2025
|
Samraat S. Raha President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,498
+0.31%
|
$4,494
$3.56 P/Share
|
May 01
2025
|
Brian J Donnelly Chief Commerical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
397,534
+37.15%
|
-
|
Apr 14
2025
|
Mark Verratti Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,085
-0.28%
|
$8,680
$8.08 P/Share
|
Apr 14
2025
|
Dale Muzzey Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
942
-0.55%
|
$7,536
$8.08 P/Share
|
Mar 25
2025
|
Natalie Munk Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
362
-0.78%
|
$3,258
$9.73 P/Share
|
Mar 24
2025
|
Paul J Diaz President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
45,139
-2.44%
|
$406,251
$9.98 P/Share
|
Mar 24
2025
|
Mark Verratti Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,701
-0.35%
|
$24,309
$9.98 P/Share
|
Mar 24
2025
|
Dale Muzzey Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,345
-0.39%
|
$12,105
$9.98 P/Share
|
Mar 24
2025
|
Kevin Richard Haas Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,901
-0.8%
|
$26,109
$9.98 P/Share
|
Mar 24
2025
|
Natalie Munk Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
982
-1.04%
|
$8,838
$9.98 P/Share
|
Mar 22
2025
|
Paul J Diaz President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
72,541
-3.65%
|
$725,410
$10.01 P/Share
|
Mar 22
2025
|
Mark Verratti Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,989
-0.64%
|
$49,890
$10.01 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.72M shares |
---|
Payment of exercise price or tax liability | 412K shares |
---|---|
Open market or private sale | 107K shares |